Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer ; volume:13 ; number:1 ; day:23 ; month:9 ; year:2013 ; pages:1-8 ; date:12.2013
BMC cancer ; 13, Heft 1 (23.9.2013), 1-8, 12.2013
- Urheber
-
Hwang, Jun-Eul
- Beteiligte Personen und Organisationen
-
Hong, Ji-Yun
Kim, Karham
Kim, Seung-Hun
Choi, Won-Young
Kim, Min-Jee
Jung, Sung-Hoon
Shim, Hyun-Jeong
Bae, Woo-Kyun
Hwang, Eu-Chang
Lee, Kyung-Hwa
Lee, Jae-Hyuk
Cho, Sang-Hee
Chung, Ik-Joo
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-13-431
- URN
-
urn:nbn:de:1111-2016030410868
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hwang, Jun-Eul
- Hong, Ji-Yun
- Kim, Karham
- Kim, Seung-Hun
- Choi, Won-Young
- Kim, Min-Jee
- Jung, Sung-Hoon
- Shim, Hyun-Jeong
- Bae, Woo-Kyun
- Hwang, Eu-Chang
- Lee, Kyung-Hwa
- Lee, Jae-Hyuk
- Cho, Sang-Hee
- Chung, Ik-Joo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?
Changes in neutrophile-to-lymphocyte ratio as predictive and prognostic biomarker in metastatic prostate cancer treated with taxane-based chemotherapy
Upfront taxane could be superior to pegylated liposomal doxorubicin (PLD): a retrospective real-world analysis of treatment sequence taxane–PLD versus PLD–taxane in patients with metastatic breast cancer
Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study
Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy
Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis
Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer
In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer
Taxane Combination Chemotherapy in Breast Cancer: Experience from a Tertiary Cancer Centre in India
A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma
Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?
Changes in neutrophile-to-lymphocyte ratio as predictive and prognostic biomarker in metastatic prostate cancer treated with taxane-based chemotherapy
Upfront taxane could be superior to pegylated liposomal doxorubicin (PLD): a retrospective real-world analysis of treatment sequence taxane–PLD versus PLD–taxane in patients with metastatic breast cancer
Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study
Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy
Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis
Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer
In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer
Taxane Combination Chemotherapy in Breast Cancer: Experience from a Tertiary Cancer Centre in India
A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma
Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?
Changes in neutrophile-to-lymphocyte ratio as predictive and prognostic biomarker in metastatic prostate cancer treated with taxane-based chemotherapy
Upfront taxane could be superior to pegylated liposomal doxorubicin (PLD): a retrospective real-world analysis of treatment sequence taxane–PLD versus PLD–taxane in patients with metastatic breast cancer
Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study
Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy
Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis
Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer
In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer
Taxane Combination Chemotherapy in Breast Cancer: Experience from a Tertiary Cancer Centre in India
A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma
Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine